Kuano to collaborate with the Alzheimer’s Research UK DDI

London, UK, 24th June 2021: Kuano Ltd., is excited to announce a research collaboration with the Alzheimer’s Research UK University College London Drug Discovery Institute (ARUK UCL DDI).  The collaboration will focus on in silico approaches to identify new leads as inhibitors of NOTUM carboxylesterase.  As part of the collaboration, Kuano will simulate the quantum transition state of the NOTUM enzyme, identifying the pharmacophore for the transition state and modelling novel inhibitors which will then be tested for their potential as leads by ARUK UCL DDI.

Dr. Parminder Ruprah, Head of Chemistry at Kuano, said:

We see this collaboration as a great opportunity to work with the UCL Drug Discovery Institute in combining our unique approach to identifying novel enzyme inhibitors with the DDI’s expertise in evaluating novel NOTUM inhibitors.  Our collaboration has the potential to expand the portfolio of chemotypes being explored targeting NOTUM in the treatment of dementia.

Dr Paul Fish, Head of Chemistry at ARUK UCL DDI said:

We are very pleased to be collaborating with Kuano in order to explore the potential for their in silico approaches to identify novel, differentiated chemical matter targeting NOTUM, a potentially important target for the treatment of degenerative neurological disorders.

About Alzheimers’s Research UK UCL Drug Design Institute:

Launched in 2015 as part of the wider Drug Discovery Alliance funded by Alzheimer’s Research UK, the ARUK UCL DDI couples sophisticated drug discovery capabilities with deep disease-specific expertise to identify and validate new therapeutic targets.

Situated in University College London’s historic Cruciform building, a key strategy is to form collaborations with academic and industrial partners to seek out new targets for neurodegenerative diseases.

For more information about ARUK UCL DDI, please visit
 https://ucl-ddi.alzheimersresearchuk.org/